Lupin Digital Health, a wholly owned subsidiary of the global pharmaceutical leader Lupin Limited, has announced a strategic collaboration with Medicover Hospitals to enhance cardiac care for patients in India.…
Lupin Limited, a leading global pharmaceutical company, has announced the acquisition of three key anti-diabetes trademarks—GIBTULIO®, GIBTULIO MET®, and AJADUO®—from Boehringer Ingelheim International GmbH. This strategic move is aimed at…
Neurocrine Biosciences,has announced that the U.S. Food and Drug Administration (FDA) has approved CRENESSITY™ (crinecerfont) capsules and oral solution for use as an adjunctive treatment to glucocorticoid replacement in adults…
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending acoramidis for marketing authorization in the European Union (EU).…
Takeda is hosting an investor R&D Day today, starting at 8:30 a.m. JST in Tokyo. The event will highlight the company’s late-stage pipeline, focusing on its transformative potential for patients…
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). This decision is based…
Eli Lilly and Company announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending Omvoh® (mirikizumab) for approval. Omvoh,…
AbbVie has announced a definitive agreement to acquire Nimble Therapeutics, a biotech company specializing in the discovery and development of innovative oral peptide therapies. This acquisition includes Nimble’s lead investigational…
Merck known as MSD outside the United States and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending…
Updated results from the OlympiA Phase III trial revealed that AstraZeneca and MSD’s Lynparza (olaparib) continues to show significant, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS),…
Pfizer and Alliance Foundation Trials, LLC (AFT) recently unveiled findings from the Phase 3 PATINA trial, highlighting the potential of IBRANCE (palbociclib) in improving outcomes for patients with hormone receptor-positive…
Cyrus Biotechnology, Inc. has announced new data demonstrating the potent activity of its engineered IgG-degrading enzyme, CYR241, in a rabbit redosing model. Importantly, the study revealed that CYR241 does not…
